The RDCRN program is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation.
-
Research
-
-
Funding & Notices
-
-
News & Media
-
About Translation
-
-
About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- NCATS Chemical Genomics Center (NCGC)
- NIH Common Fund Programs
- Pfizer's Centers for Therapeutic Innovation (CTI) for NIH Researchers
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Trans-NIH RNAi Facility (TNRF)
- Therapeutics for Rare and Neglected Diseases (TRND)
-